Baidu
map

铁蛋白或将成为IrAEs的诊断、鉴别诊断及预后的标志物

2021-08-12 kate MedSci原创

免疫检查点抑制剂(ICIs)能恢复T细胞的增殖和效应能力,狙击逃逸的肿瘤细胞,是当前实体瘤和血液肿瘤领域炙手可热的明星药。

免疫检查点抑制剂(ICIs)能恢复T细胞的增殖和效应能力,狙击逃逸的肿瘤细胞,是当前实体瘤和血液肿瘤领域炙手可热的明星药。

但它会产生免疫相关不良事件(irAEs)。IrAEs可影响任何组织或器官,处理稍有不当,可直接影响抗肿瘤药物带来的生存获益效果。

但它与化疗、靶向治疗或感染引起的AE又很相似,要想把他们完全区分开来并非易事。对此,近期有学者提出:铁蛋白可用作IrAEs的诊断、鉴别诊断及预后的标志物。

该研究于今年8月11日发表于Cancer Biol Med上。

研究方法

研究者共纳入318名恶性肿瘤患者,其中231例患者正在接受PD-1抑制剂或联合化疗的治疗方案,87例患者仅接受化疗的治疗方案。

在231例患者中,可分为irAE组(90人,有irAE)、非irAE组(70人,没有irAE)、AE组(4人,有AE)以及非irAE-无AE组(67人,既无irAE,也无AE)。

而在87例患者中,又可分为AE组(60人,有AE)和无AE组(27人,无AE)。

研究结论

通过历时4个月的血清铁蛋白监测发现:

irAE组发生不良事件时,铁蛋白含量(正常范围35-150μg/L)从基线值86μg/L上升到中位值927μg/L。

irAE组在发生不良事件时,铁蛋白含量明显高于非irAE组和AE组。

同时,研究者还发现irAE组经治疗后,患者铁蛋白含量会逐渐降至正常范围内。

由此可以看出,铁蛋白是一种能判断患者是否患上irAE及预后情况的标志物。

 

文献来源

Weihong Zhang,et al.Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.Cancer Biol Med. 2021 Aug 11;j.issn.2095-3941.2021.0037.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1841720, encodeId=a5181841e20cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Nov 14 22:11:33 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010168, encodeId=2db3101016818, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Sat Aug 21 22:27:57 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506966, encodeId=25d71506966e0, content=<a href='/topic/show?id=a66b9624e0c' target=_blank style='color:#2F92EE;'>#鉴别诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96247, encryptionId=a66b9624e0c, topicName=鉴别诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77179846395, createdName=Homburg, createdTime=Sat Aug 14 09:11:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007358, encodeId=6e0c100e358d1, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039a5568962, createdName=ms4000000019275503, createdTime=Thu Aug 12 18:29:31 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1841720, encodeId=a5181841e20cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Nov 14 22:11:33 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010168, encodeId=2db3101016818, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Sat Aug 21 22:27:57 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506966, encodeId=25d71506966e0, content=<a href='/topic/show?id=a66b9624e0c' target=_blank style='color:#2F92EE;'>#鉴别诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96247, encryptionId=a66b9624e0c, topicName=鉴别诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77179846395, createdName=Homburg, createdTime=Sat Aug 14 09:11:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007358, encodeId=6e0c100e358d1, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039a5568962, createdName=ms4000000019275503, createdTime=Thu Aug 12 18:29:31 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-08-21 ms2658711348342440

    学习了 谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1841720, encodeId=a5181841e20cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Nov 14 22:11:33 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010168, encodeId=2db3101016818, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Sat Aug 21 22:27:57 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506966, encodeId=25d71506966e0, content=<a href='/topic/show?id=a66b9624e0c' target=_blank style='color:#2F92EE;'>#鉴别诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96247, encryptionId=a66b9624e0c, topicName=鉴别诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77179846395, createdName=Homburg, createdTime=Sat Aug 14 09:11:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007358, encodeId=6e0c100e358d1, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039a5568962, createdName=ms4000000019275503, createdTime=Thu Aug 12 18:29:31 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1841720, encodeId=a5181841e20cb, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Nov 14 22:11:33 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010168, encodeId=2db3101016818, content=学习了 谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Sat Aug 21 22:27:57 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506966, encodeId=25d71506966e0, content=<a href='/topic/show?id=a66b9624e0c' target=_blank style='color:#2F92EE;'>#鉴别诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96247, encryptionId=a66b9624e0c, topicName=鉴别诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77179846395, createdName=Homburg, createdTime=Sat Aug 14 09:11:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007358, encodeId=6e0c100e358d1, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039a5568962, createdName=ms4000000019275503, createdTime=Thu Aug 12 18:29:31 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-08-12 ms4000000019275503

    很棒

    0

相关资讯

Br J Cancer:新型诊断模型鉴定食道鳞状细胞癌的相关标志物和脂质失调

食道癌(EC)是一种常见的高发生率和高死亡率的恶性肿瘤。在全球范围内,EC是第六大癌症死亡原因,且呈现上升趋势。

Stroke:中性粒细胞计数作为预测动脉瘤性蛛网膜下腔出血患者住院死亡率有前景的标志物

在动脉瘤性蛛网膜下腔出血患者中,入院时较高的中性粒细胞计数与死亡率和医院获得性感染风险增加相关。中性粒细胞计数是一个简单、有用的标志物,对动脉瘤性蛛网膜下腔出血患者具有重要的预后价值。

Clin Cancer Res:预测仑伐替尼(Lenvatinib)在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究

基线高表达的VEGF, FGF21,和ANG2可能是较差OS的预后标志物;而基线高表达的FGF21是仑伐替尼较索拉非尼改善预后的预测标志物,这些还需要进一步的证实。

Cancers:预测帕博利珠单抗(Pembrolizumab)治疗非小细胞肺癌患者持续应答的标志物和基因集

Cancers:预测帕博利珠单抗(Pembrolizumab)治疗非小细胞肺癌患者持续应答的标志物和基因集

Br J Cancer:RNAscope技术检测α-甲胎蛋白mRNA水平为肝细胞癌的新型的高度特异性标志物

肝细胞癌(HCC)作为全球癌症相关死亡的主要原因之一,占全球原发性肝癌的70–90%。

Br J Cancer:CD4、CD8和 FOXP3阳性免疫细胞可作为BRCA1/2相关乳腺癌死亡率的预测标志物

约3-5%的乳腺癌患者具有BRCA1或BRCA2基因突变,这是约28%的高危遗传性乳腺癌的病因。

Baidu
map
Baidu
map
Baidu
map